Replicate Bioscience Secures Grants for Innovative HIV and Malaria Vaccines Using srRNA Technology
Advancements in Vaccine Development
In a significant move to combat two of the world's most pressing infectious diseases, Replicate Bioscience has been awarded grants totaling approximately $7 million from the Gates Foundation. This funding aims to support the company's pioneering work in self-replicating RNA (srRNA) technology, which has the potential to revolutionize vaccine development for HIV and malaria.
Breaking New Ground with srRNA Technology
Replicate Bioscience, based in San Diego, is making waves in the clinical-stage biopharmaceutical sector by introducing novel srRNA technology targeted at infectious diseases, immunology, and various therapeutic applications. The recent grants include approximately $3.5 million for the development of a low-dose, multigenic RNA-based vaccine against malaria, and another $3.5 million to create an innovative self-replicating RNA-based candidate for HIV.
“We are excited to expedite the development of our HIV and malaria vaccine candidates with the Gates Foundation's financial backing,
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.